http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105055729-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97c915fa24a8ec723bd0c24e350e97b2 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-888 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| filingDate | 2015-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cbf4f7c402714bfc7012032e0159668 |
| publicationDate | 2015-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105055729-A |
| titleOfInvention | Chinese herb composition for treating liver stagnation and spleen deficiency and blood stasis type hepatitis B liver fibrosis |
| abstract | The invention belongs to the technical field of medicine, and particularly relates to a Chinese herb composition for treating liver stagnation and spleen deficiency and blood stasis type hepatitis liver fibrosis. The Chinese herb composition comprises, by weight, 8-16 parts of chicken foot taros, 5-13 parts of Chinese elder herbs, 8-16 parts of Chinese flat cabbage, 8-16 parts of sweet osmanthus essence, 4-8 parts of manglietia yuyuanensis fruits, 4-8 parts of shrubberry rhodiola roots, 8-16 parts of rust-colored crotalaria herbs with roots, 5-13 parts of lasianthus hirsutus, 5-13 parts of cortex acanthopanacis, 5-13 parts of fiveleaf akebia fruits, 4-8 parts of physalis angulata and 4-8 parts of liquorice roots. All the herbs are used in cooperation to have the effects of soothing the liver, reinforcing the spleen, tonifying the kidneys and removing stasis, and the Chinese herb composition meets the pathogenesis of liver stagnation and spleen deficiency and blood stasis type hepatitis liver fibrosis, can relieve clinical symptoms of a patient with the liver fibrosis and particularly has remarkable relieving improvements on hypochondrium distending pain, abdominal distension and strength lacking. Serum AST and ALT and levels of four indicators of liver fibrosis can be reduced, the liver function can be improved, and the degree of liver fibrosis can be decreased. |
| priorityDate | 2015-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 100.